表紙
市場調查報告書
商品編碼
989964

慢性腎臟病的腎臟貧血:到2029年的流行病學預測

Chronic Kidney Disease-Anemia - Epidemiology Forecast to 2029

出版日期: | 出版商: GlobalData | 英文 30 Pages | 訂單完成後即時交付

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

八個主要國家(美國,法國,德國,意大利,西班牙,英國,日本,中國)的慢性腎臟病導致的腎性貧血的診斷患病率呈上升趨勢,預計2019年將以1.13%的年增長率增長。從每年的4,025,003例到2029年的4,479,119例。中國是八個主要國家中患病率最高的國家,預計2029年的患病率將為2,202,294。

該報告調查了八個主要國家(美國,法國,德國,意大利,西班牙,英國,日本,中國)因慢性腎臟病引起的腎性貧血市場,流行病學,市場趨勢和預測,提供了諸如影響等方面的信息。 COVID-19。

目錄

第1章目錄

  • 表列表
  • 圖片清單

第2章執行摘要

  • 相關報告
  • 未來報告

第3章流行病學

  • 疾病背景
  • 危險因素和合併症
  • 世界歷史趨勢
  • 預測調查方法
    • 來源
    • 預測的前提條件和方法
    • 診斷為腎性貧血的患病率和診斷為腎性貧血的患病率
    • 因透析依賴而診斷出的腎性貧血患病率
    • 根據貧血原因診斷出的腎性貧血患病率
  • 腎性貧血的流行病學預測(2019-2029)
    • 診斷患病率
    • 按年齡分類:確診患病率
    • 性別:已診斷患病率
    • 分階段:診斷病例
    • 因透析依賴而診斷出的腎性貧血患病率
    • 根據貧血原因診斷出的腎性貧血患病率
  • 討論
    • 流行病學預測見解
    • COVID-19的影響
    • 分析的局限性
    • 分析的優勢

第4章附錄

  • 參考
  • 主要調查:處方者調查
  • 關於作者
  • 關於全球數據
  • 聯繫我們
  • 免責聲明
目錄
Product Code: GDHCER263-21

Chronic kidney disease (CKD) is a condition characterized by a gradual loss of kidney function over time. Anemia is a frequent complication of CKD. By definition, anemia refers to an absolute reduction of the total number of circulating red blood cells (RBCs). In CKD-anemia, the production of erythropoietin decreases, which leads to low RBC count and hence causes anemia. Anemia is also associated with increased blood loss in dialysis patients. Anemia might begin to develop in the early stages of CKD and it tends to worsen as CKD progresses (National Institute of Diabetes and Digestive and Kidney Diseases, 2014; National Kidney Foundation, 2016).

GlobalData epidemiologists utilized historical data obtained from peer-reviewed articles and population-based studies to build the forecast for the diagnosed prevalent cases of CKD-Anemia in the 8MM. GlobalData epidemiologists applied the prevalence of CKD-anemia drawn from the above sources to each country's CKD population to calculate the diagnosed prevalent cases for CKD-anemia.

The following data describes the epidemiology of CKD-anemia. In the 8MM, the diagnosed prevalent cases of CKD-anemia are expected to increase from 4,025,003 cases in 2019 to 4,479,119 cases in 2029, at an Annual Growth Rate (AGR) of 1.13%. In 2029, China will have the highest number of diagnosed prevalent cases of CKD-anemia in the 8MM with 2,002,294 diagnosed prevalent cases, whereas the UK will have the lowest number of 73,900 diagnosed prevalent cases in 2029. In the 8MM in 2019, stage V made up 35.39% of all diagnosed prevalent CKD-anemia cases with 1,424,506 cases, followed by stage IIIa and stage IV at 19.22% (773,718 cases) and 15.42% (620,702 cases), respectively.

Scope

  • The CKD-Anemia Epidemiology Report provides an overview of the risk factors and global trends of chronic kidney disease-anemia (CKD-anemia) in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China).
  • The report includes a 10-year epidemiology forecast for the diagnosed prevalent cases of CKD-anemia. The diagnosed prevalent cases of CKD-anemia are segmented by age (≥18 years), sex, stage, as well as by cause of anemia (kidney-related causes and other causes), and by dialysis dependency (dialysis-dependent and non-dialysis-dependent) in the 8MM. The model additionally provides diagnosed and total prevalent cases of CKD segmented by age (≥18 years), sex, and stage.
  • The CKD-anemia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The CKD-Anemia Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global CKD-anemia markets.
  • Quantify patient populations in the global CKD-anemia markets to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for CKD-anemia therapeutics in each of the markets covered.
  • Understand magnitude of CKD-anemia population by its severity.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Chronic Kidney Disease-Anemia: Executive Summary

  • 2.1 Related Reports
  • 2.2 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Prevalent Cases of CKD-Anemia and Diagnosed Prevalent Cases of CKD-Anemia by Stage
    • 3.4.4 Diagnosed Prevalent Cases of CKD-Anemia Based on Dialysis Dependency
    • 3.4.5 Diagnosed Prevalent Cases of CKD-Anemia Based on Cause of Anemia
  • 3.5 Epidemiological Forecast for CKD-Anemia (2019-2029)
    • 3.5.1 Diagnosed Prevalent Cases of CKD-Anemia
    • 3.5.2 Age-Specific Diagnosed Prevalent Cases of CKD-Anemia
    • 3.5.3 Sex-Specific Diagnosed Prevalent Cases of CKD-Anemia
    • 3.5.4 Diagnosed Prevalent Cases of CKD-Anemia by Stage
    • 3.5.5 Diagnosed Prevalent Cases of CKD-Anemia Based on Dialysis Dependency
    • 3.5.6 Diagnosed Prevalent Cases of CKD-Anemia Based on Cause of Anemia
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 Coronavirus Disease 2019 Impact
    • 3.6.3 Limitations of the Analysis
    • 3.6.4 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 Primary Research - Prescriber Survey
  • 4.3 About the Authors
    • 4.3.1 Epidemiologist
    • 4.3.2 Reviewers
    • 4.3.3 Global Director of Therapy Analysis and Epidemiology
    • 4.3.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.4 About GlobalData
  • 4.5 Contact Us
  • 4.6 Disclaimer

List of Tables

List of Tables

  • Table 1: Risk Factors and Comorbidities for CKD-Anemia
  • Table 2: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Prevalent Cases of CKD-Anemia, Both Sexes, N, Ages ≥18 Years, 2019 and 2029
  • Figure 2: 8MM, Diagnosed Prevalence of CKD-Anemia, Men and Women, %, Ages ≥18 Years, 2019
  • Figure 3: 8MM, Sources Used and Not Used to Forecast the Diagnosed Prevalent Cases of CKD-Anemia, Diagnosed Prevalent Cases of CKD-Anemia by Stage, and Diagnosed Prevalent Cases of CKD-Anemia Based on Dialysis Dependence
  • Figure 4: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of CKD-Anemia Based on Cause of Anemia
  • Figure 5: 8MM, Diagnosed Prevalent Cases of CKD-Anemia, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 6: 8MM, Diagnosed Prevalent Cases of CKD-Anemia by Age, N, Both Sexes, 2019
  • Figure 7: 8MM, Diagnosed Prevalent Cases of CKD-Anemia by Sex, N, Ages ≥18 Years, 2019
  • Figure 8: 8MM, Diagnosed Prevalent Cases of CKD-Anemia by Stage, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 9: 8MM, Diagnosed Prevalent Cases of CKD-Anemia Based on Dialysis Dependence, N, Both Sexes, Ages ≥18 Years, 2019
  • Figure 10: 8MM, Diagnosed Prevalent Cases of CKD-Anemia Based on Cause of Anemia, N, Both Sexes, Ages ≥18 Years, 2019